Latest Advances in Myeloma Treatment: ASCO and EHA 2018 Highlights

Hear Talk Audio


Latest Advances in Myeloma Treatment: ASCO and EHA 2018 Highlights

The treatment field of Multiple Myeloma continues to move forward as novel agents and treatment combinations expand. Whether you are standard risk patient or belong to high-risk group, treatment paradigms are getting better. We are talking to Dr. Mateos on Myeloma research and treatment modalities discussed and presented at the recently concluded American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings.

Panelists

Talk Recorded on July 9, 2018, 10 a.m. EST </> Embed Find Multiple Myeloma Trials




  • E July 5, 2018, 10:24 a.m.  US/Eastern

    Is there any new evidence that suggests that early treatment with RVD on newly diagnosed low risk early myeloma with no CRAB features can produce an overall better survival rate than not treating at all and waiting for progression? Also, can very early treatment be viewed as with curative intent?

  • L June 29, 2018, 11:55 a.m.  US/Eastern

    8 year patient